Dormant Colorectal Cancer Cells Evade Chemo by Mimicking Embryonic Diapause
Cancer cells that downregulate SMC4 enter a low-proliferation, diapause-like state that resists standard chemotherapy, revealing a dangerous survival mechanism.
Summary
Researchers studying colorectal cancer discovered that when a protein called SMC4 is reduced, cancer cells can enter a dormant, diapause-like state — similar to the suspended embryonic development seen in some animals. These dormant cells divide very slowly and, critically, become resistant to chemotherapy, which typically targets rapidly dividing cells. This finding helps explain why some colorectal cancers can persist or relapse even after seemingly successful treatment. Understanding how these cells enter and exit this dormant state could point toward new therapeutic strategies that target quiescent cancer cells, which are currently a major blind spot in oncology. This is a corrected publication (erratum) of an original 2023 Cell Metabolism study.
Detailed Summary
Colorectal cancer remains one of the most common and deadly malignancies worldwide, and treatment resistance is a central challenge. A key but poorly understood mechanism involves cancer cells entering a dormant state that allows them to survive chemotherapy and later re-emerge. This research addresses that problem directly.
The study, originally published in Cell Metabolism in 2023 and now corrected in a 2026 erratum, examines what happens when the structural maintenance of chromosomes protein 4 (SMC4) is attenuated in colorectal cancer cells. SMC4 is part of the condensin complex critical for chromosome organization and cell division.
When SMC4 levels were reduced, colorectal cancer cells transitioned into a diapause-like state — a condition analogous to the temporary suspension of embryonic development observed in certain mammals under adverse environmental conditions. In cancer, this state is characterized by dramatically reduced proliferation rates and significant insensitivity to conventional chemotherapy agents.
The implications are clinically significant. Standard chemotherapy is designed to kill rapidly dividing cells. Cancer cells that can slow their division, essentially going into biological hibernation, become largely invisible to these treatments. If even a small population of tumor cells can adopt this strategy, they may survive a full course of chemotherapy and seed future relapse.
This work suggests that therapeutic strategies must account for dormant, diapause-like cancer cell populations. Identifying the molecular switches that control entry into and exit from this state — with SMC4 attenuation as one such trigger — could enable combination therapies that eliminate both proliferating and dormant cancer cells. Caveats include that this summary is based on an erratum notice and abstract only, limiting full assessment of the original experimental methodology and scope.
Key Findings
- Reducing SMC4 protein in colorectal cancer cells triggers a dormant, diapause-like low-proliferation state.
- Diapause-like cancer cells show significantly reduced sensitivity to standard chemotherapy.
- This dormancy mechanism may explain treatment resistance and relapse after apparent remission.
- SMC4 attenuation is identified as a molecular switch controlling cancer cell quiescence.
- Targeting dormant cancer cell populations may require entirely different therapeutic strategies.
Methodology
This is an erratum correcting the original Cell Metabolism 2023 study (35(9):1563-1579). The original research used colorectal cancer cell models with SMC4 attenuation to characterize diapause-like cellular states. Full experimental details — including in vitro vs. in vivo models, specific chemotherapy agents tested, and genetic tools used — are not accessible from the abstract alone.
Study Limitations
This summary is based on the abstract and erratum notice only — the full paper is not open access, limiting assessment of methodology, sample sizes, and statistical rigor. As an erratum, the precise nature of the correction to the original 2023 paper is unknown and may affect interpretation of specific findings. Findings are based on cancer cell models and require further validation in clinical or in vivo contexts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.